Following my last article on Novo Nordisk ( NVO ), the stock price has dropped by 20%. The Danish healthcare heavyweight is now trading at a forward P/E of approximately 13 , highlighting significant undervaluationDear Reader,I am a Senior Derivatives Expert with over 10 years of experience in the field of Asset Management, specializing in equity analysis and research, macroeconomics, and risk-managed portfolio construction. My professional background covers both institutional and private client asset manag ...